evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1 questions · 1 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Ocrelizumab vs interferon beta‐1a

Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).

1 finding from 1 review